drugset

drugset / Trial / NCT04080947

The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis

NCT04080947 ↗

Phase 1/2 Completed 56 enrolled Sadat City University

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the current study is to evaluate the safety and efficay of Montelukast in treatment of patients with fatty liver disease.

Timeline

Start: 2019-08-01
Primary completion: 2021-08-31
Completion: 2022-03-15

Outcome

Met primary endpoint

paper montelukast showed a statistically significant improvement in liver stiffness PMID 34214585 ↗

Publications

Abdallah MS, Eldeen AH, Tantawy SS, Mostafa TM. The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial. Eur J Pharmacol. 2021 Sep 5;906:174295. doi: 10.1016/j.ejphar.2021.174295. Epub 2021 Jun 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Montelukast	Other / unclassified	10 mg	Oral

Indications